Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)

NCT00840931 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

DRUG: lenalidomide
BIOLOGICAL: bystander vaccine

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]